Anebulo Pharmaceuticals, Inc. (ANEB) Tops Q2 EPS by 8c Feb 12, 2026 04:16PM
Anebulo Pharmaceuticals to delist from NASDAQ and deregister with SEC Feb 6, 2026 09:00AM
Anebulo tender offer oversubscribed with 4.9M shares tendered Jan 27, 2026 09:02AM
Anebulo abandons reverse stock split, launches tender offer instead Dec 22, 2025 09:01AM
Anebulo Pharmaceuticals, Inc. (ANEB) Tops Q1 EPS by 7c Nov 13, 2025 04:08PM


Sep 29, 2025 04:07PM Anebulo Pharmaceuticals, Inc. (ANEB) Reports In-Line Q4 EPS
Sep 12, 2025 07:30AM Anebulo explores strategic alternatives after receiving takeover interest
Jul 23, 2025 08:01AM Anebulo Pharmaceuticals plans reverse stock split to go private
May 22, 2025 08:38AM Anebulo Pharmaceuticals (ANEB) PT Lowered to $3 at Benchmark
May 13, 2025 04:05PM Anebulo Pharmaceuticals, Inc. (ANEB) Tops Q3 EPS by 4c
Feb 25, 2025 10:28AM Benchmark Reiterates Speculative Buy Rating on Anebulo Pharmaceuticals (ANEB)
Dec 23, 2024 09:16AM Anebulo Pharmaceuticals (ANEB) Announces Positive Regulatory Update for Selonabant
Nov 13, 2024 04:25PM Anebulo Pharmaceuticals, Inc. (ANEB) Reports Q1 Loss of $0.08
Oct 1, 2024 06:53AM Benchmark Reiterates Speculative Buy Rating on Anebulo Pharmaceuticals (ANEB)
Jul 22, 2024 07:01AM Anebulo Pharmaceuticals (ANEB) Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects